Answers are grounded in this paper and cite their sources.
Summary We retrospectively analysed 646 chronic lymphocytic leukaemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana‐Farber Cancer Institute from 2014 to 2023. Among them, 122 underwent next‐generation sequencing (NGS) during or at the next office visit after BTKi therapy (ibrutinib [IBR], 85; acalabrutinib [ACA], 23; pirtobrutinib [PIR], 9; vecabrutinib [VEC], 1; zanubrutinib [ZANU], 4). Compared with the non‐progressor (NP) group ( N = 75), patients with NGS at progression (PD group, N = 47) more commonly had 17p deletion, complex karyotype, heavier prior treatment exposure and prior exposure to a different BTKi before the current regimen. We found 321 mutations in 67 genes, with more mutations in the PD group (231 mutations), including 39 BTK ( BTK C481S/F/R/Y, L528W and T474I/L) and 26 phospholipase C gamma 2 ( PLCG2 ) mutations. Among the 12 PD patients with serial samples, all acquired new or expanded BTK or TP53 mutations. Complex karyotype, specifically 8p loss, was significantly enriched in the PD group. tumour protein p53 ( TP53 ), splicing factor 3b subunit 1 ( SF3B1 ), protein phosphatase, Mg 2 + /Mn 2 + dependent 1D ( PPM1D ) and notch receptor 2 ( NOTCH2 ) mutations were also significantly more prevalent in the PD group (all p < 0.05). Additionally, pathogenic mitogen‐activated protein kinase (MAPK) pathway mutations trended more common and had higher variant allele frequencies (VAFs) in the PD group ( p = 0.047). These findings suggest that TP53 aberration and 8p‐loss‐associated complex karyotype, as well as several non‐BTK driver mutations, are enriched in BTKi‐resistant patients.
No takes yet. Share an insight, caveat, or question.
Mashima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: